Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAB7: 7 vs 14 Days of Antibiotics for Uncomplicated S. Aureus Bacteremia
NCT03514446Phase 4Unknown
- Start
- Jun 2018
- Primary completion
- May 2021
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Staphylococcus aureus bacteremia (SAB) (2 arms). Primary endpoint: 90-day survival without clinical or microbiological failure to treatment or relapse. Status: unknown.
02
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT03514446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03514446.